Safety and Efficacy of Favipiravir for the management of COVID-19 Patients: A Randomized Control Trial

{ 'indexed': {'date-parts': [[2022, 5, 12]], 'date-time': '2022-05-12T03:40:55Z', 'timestamp': 1652326855425}, 'reference-count': 30, 'publisher': 'Elsevier BV', 'license': [ { 'start': { 'date-parts': [[2022, 5, 1]], 'date-time': '2022-05-01T00:00:00Z', 'timestamp': 1651363200000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://www.elsevier.com/tdm/userlicense/1.0/'}, { 'start': { 'date-parts': [[2022, 4, 22]], 'date-time': '2022-04-22T00:00:00Z', 'timestamp': 1650585600000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'http://creativecommons.org/licenses/by-nc-nd/4.0/'}], 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'published-print': {'date-parts': [[2022, 5]]}, 'DOI': '10.1016/j.clinpr.2022.100145', 'type': 'journal-article', 'created': {'date-parts': [[2022, 5, 12]], 'date-time': '2022-05-12T03:11:37Z', 'timestamp': 1652325097000}, 'page': '100145', 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': 'Safety and Efficacy of Favipiravir for the management of COVID-19 Patients: A Randomized Control ' 'Trial', 'prefix': '10.1016', 'author': [ {'given': 'S.M. Abdur', 'family': 'Rahman', 'sequence': 'first', 'affiliation': []}, {'given': 'Ahmedul', 'family': 'Kabir', 'sequence': 'additional', 'affiliation': []}, {'given': 'ABM', 'family': 'Abdullah', 'sequence': 'additional', 'affiliation': []}, {'given': 'Md', 'family': 'Billal Alam', 'sequence': 'additional', 'affiliation': []}, {'given': 'Khan Abul Kalam', 'family': 'Azad', 'sequence': 'additional', 'affiliation': []}, {'given': 'Md', 'family': 'Titu Miah', 'sequence': 'additional', 'affiliation': []}, {'given': 'Syed Ghulam Mogni', 'family': 'Mowla', 'sequence': 'additional', 'affiliation': []}, {'given': 'Sudip Ranjan', 'family': 'Deb', 'sequence': 'additional', 'affiliation': []}, {'given': 'Mohammad Robed', 'family': 'Amin', 'sequence': 'additional', 'affiliation': []}, {'given': 'Muhammad', 'family': 'Asaduzzaman', 'sequence': 'additional', 'affiliation': []}], 'member': '78', 'reference': [ { 'issue': '4', 'key': '10.1016/j.clinpr.2022.100145_b0005', 'doi-asserted-by': 'crossref', 'first-page': '401', 'DOI': '10.1002/jmv.25678', 'article-title': 'Outbreak of pneumonia of unknown etiology in Wuhan China: the mystery ' 'and the miracle', 'volume': '92', 'author': 'Lu', 'year': '2020', 'journal-title': 'J Med Virol.'}, { 'issue': '11', 'key': '10.1016/j.clinpr.2022.100145_b0010', 'doi-asserted-by': 'crossref', 'first-page': '1061', 'DOI': '10.1001/jama.2020.1585', 'article-title': 'Clinical characteristics of 138 hospitalized patients with 2019 novel ' 'coronavirus-infected pneumonia in Wuhan', 'volume': '323', 'author': 'Wang', 'year': '2020', 'journal-title': 'JAMA'}, { 'issue': '10223', 'key': '10.1016/j.clinpr.2022.100145_b0015', 'doi-asserted-by': 'crossref', 'first-page': '497', 'DOI': '10.1016/S0140-6736(20)30183-5', 'article-title': 'Clinical features of patients infected with 2019 novel coronavirus in ' 'Wuhan', 'volume': '395', 'author': 'Huang', 'year': '2020', 'journal-title': 'China. Lancet'}, { 'issue': '10229', 'key': '10.1016/j.clinpr.2022.100145_b0020', 'doi-asserted-by': 'crossref', 'first-page': '1054', 'DOI': '10.1016/S0140-6736(20)30566-3', 'article-title': 'Clinical course and risk factors for mortality of adult inpatients with ' 'COVID-19 in Wuhan, China:a retrospective cohort study', 'volume': '395', 'author': 'Zhou', 'year': '2020', 'journal-title': 'Lancet'}, { 'issue': '10229', 'key': '10.1016/j.clinpr.2022.100145_b0025', 'doi-asserted-by': 'crossref', 'first-page': '1014', 'DOI': '10.1016/S0140-6736(20)30633-4', 'article-title': 'Clinical course and mortality risk of severe COVID-19', 'volume': '395', 'author': 'Weiss', 'year': '2020', 'journal-title': 'Lancet'}, { 'key': '10.1016/j.clinpr.2022.100145_b0030', 'unstructured': 'Worldometer: https://www.worldometers.info/coronavirus/. Accessed 5th ' 'April, 2021.'}, { 'issue': '1', 'key': '10.1016/j.clinpr.2022.100145_b0035', 'first-page': '157', 'article-title': 'WHO declares COVID-19 a pandemic', 'volume': '91', 'author': 'Cucinotta', 'year': '2020', 'journal-title': 'Acta Biomed'}, { 'issue': '5', 'key': '10.1016/j.clinpr.2022.100145_b0040', 'doi-asserted-by': 'crossref', 'first-page': '676', 'DOI': '10.1177/10105395211014345', 'article-title': 'Major depressive and Generalized anxiety disorders among university ' 'students during the second wave of COVID-19 outbreak in Bnagladesh', 'volume': '33', 'author': 'Hossain', 'year': '2021', 'journal-title': 'Asia Pac. J. Pubic Health'}, { 'key': '10.1016/j.clinpr.2022.100145_b0045', 'doi-asserted-by': 'crossref', 'first-page': '185', 'DOI': '10.1016/j.ijsu.2020.04.018', 'article-title': 'The Socio-economic implications of the coronavirus pandemic (COVID-19): ' 'A review', 'volume': '78', 'author': 'Nicola', 'year': '2020', 'journal-title': 'Int. J. Surg.'}, { 'issue': '13', 'key': '10.1016/j.clinpr.2022.100145_b0050', 'doi-asserted-by': 'crossref', 'first-page': '5343', 'DOI': '10.3390/su12135343', 'article-title': 'Covid-19 and the UN Sustainable Development Goals: Threat to Solidarity ' 'or an Opportunity?', 'volume': '12', 'author': 'Leal Filho', 'year': '2020', 'journal-title': 'Sustainability'}, { 'issue': '8', 'key': '10.1016/j.clinpr.2022.100145_b0055', 'doi-asserted-by': 'crossref', 'first-page': '1009', 'DOI': '10.1080/14787210.2021.1864327', 'article-title': 'Repurposing therapeutic agents againsts SARS-CoV-2 infection: most ' 'promising and neoteric progress', 'volume': '19', 'author': 'Hossain', 'year': '2021', 'journal-title': 'Expert Rev Antiinfective Therapy.'}, { 'key': '10.1016/j.clinpr.2022.100145_b0060', 'doi-asserted-by': 'crossref', 'DOI': '10.3389/fphar.2021.659577', 'article-title': 'Therapeutic effectiveness and safety of repurposing drugs for the ' 'treatment of COVID-19: position standing in 2021', 'volume': '12', 'author': 'Alam', 'year': '2021', 'journal-title': 'Front Pharmacol.'}, { 'issue': '3', 'key': '10.1016/j.clinpr.2022.100145_b0065', 'doi-asserted-by': 'crossref', 'first-page': '149', 'DOI': '10.1038/d41573-020-00016-0', 'article-title': 'Therapeutic options for the 2019 novel coronavirus (2019-nCoV)', 'volume': '19', 'author': 'Li', 'year': '2020', 'journal-title': 'Nat Rev Drug Discov.'}, { 'key': '10.1016/j.clinpr.2022.100145_b0070', 'unstructured': 'NIH US. National Library of Medicine ClinicalTrial.gov. ' 'https://clinicaltrials.gov/ct2/home.Accessed September 5, 2020.'}, { 'issue': '2', 'key': '10.1016/j.clinpr.2022.100145_b0075', 'doi-asserted-by': 'crossref', 'first-page': '446', 'DOI': '10.1016/j.antiviral.2013.09.015', 'article-title': 'Favipiravir (T-705), a novel viral RNA polymerase inhibitor', 'volume': '100', 'author': 'Furuta', 'year': '2013', 'journal-title': 'Antiviral Res.'}, { 'issue': '1', 'key': '10.1016/j.clinpr.2022.100145_b0080', 'doi-asserted-by': 'crossref', 'first-page': '79', 'DOI': '10.1017/dmp.2014.151', 'article-title': 'Favipiravir: a new medication for the ebola virus disease pandemic', 'volume': '9', 'author': 'Nagata', 'year': '2015', 'journal-title': 'Disaster Medicine and Public Health preparedness'}, { 'key': '10.1016/j.clinpr.2022.100145_b0085', 'doi-asserted-by': 'crossref', 'first-page': '85', 'DOI': '10.1016/j.antiviral.2018.03.003', 'article-title': 'Favipiravir as a potential countermeasure against neglected and ' 'emerging RNA viruses', 'volume': '153', 'author': 'Delang', 'year': '2018', 'journal-title': 'Antiviral Res.'}, { 'issue': '6', 'key': '10.1016/j.clinpr.2022.100145_b0090', 'doi-asserted-by': 'crossref', 'first-page': '2517', 'DOI': '10.1128/AAC.01739-09', 'article-title': 'In vitro antiviral activity of favipiravir (T-705) against ' 'drug-resistant influenza and 2009 a (H1N1) viruses', 'volume': '54', 'author': 'Sleeman', 'year': '2010', 'journal-title': 'Antimicrob Agents Chemother.'}, { 'issue': '3', 'key': '10.1016/j.clinpr.2022.100145_b0095', 'doi-asserted-by': 'crossref', 'first-page': '269', 'DOI': '10.1038/s41422-020-0282-0', 'article-title': 'Remdesivir and chloroquine effectively inhibit the recently emerged ' 'novel coronavirus (2019nCoV) in vitro', 'volume': '30', 'author': 'Wang', 'year': '2020', 'journal-title': 'Cell Res'}, { 'key': '10.1016/j.clinpr.2022.100145_b0100', 'article-title': 'Experimental treatment with favipiravir for COVID-19: An open-label ' 'control study', 'author': 'Cai', 'year': '2020', 'journal-title': 'Engineering (Beijing)'}, { 'key': '10.1016/j.clinpr.2022.100145_b0105', 'unstructured': 'Roser M, et.al. Coronavirus Disease (COVID-19)-Statistics and Research. ' 'Published online at OurworldData.org. retrieved from ' 'https://ourworldindata.org/coronavirus. Accessed 8 Sep 2020.'}, { 'key': '10.1016/j.clinpr.2022.100145_b0110', 'doi-asserted-by': 'crossref', 'DOI': '10.3389/fimmu.2020.01991', 'article-title': 'The impact of Pre-existing comorbidities and Therapeutic Interventions ' 'on COVID-19', 'volume': '11', 'author': 'Callender', 'year': '2020', 'journal-title': 'Front. Immunol.'}, { 'key': '10.1016/j.clinpr.2022.100145_b0115', 'unstructured': 'Pharmaceuticals and Medical Devices Agency, Report on the deliberation ' 'results – avigan. Japan; Evaluation and Licensing Division, ' 'Pharmaceutical and Food Safety Bureau, 2011. Available at: ' 'www.pmda.go.jp/files/000210319.pdf. Accessed September 20, 2020.'}, { 'key': '10.1016/j.clinpr.2022.100145_b0120', 'unstructured': 'COVID-19: Glenmark’s favipiravir shows encouraging results in phase 3 ' 'clinical trial. The Indian Express. ' 'https://www.newindianexpress.com/nation/2020/jul/23/covid-19-glenmarks-favipiravir-shows-encouraging-results-in-phase-3-clinical-trial-2173500.html. ' 'Accessed Septembe 23r, 2020.'}, { 'key': '10.1016/j.clinpr.2022.100145_b0125', 'article-title': 'Favipiravir versus arbidol for COVID-19: A randomized clinical trial', 'author': 'Chen', 'year': '2020', 'journal-title': 'medRxiv.'}, { 'key': '10.1016/j.clinpr.2022.100145_b0130', 'unstructured': 'Trial site news. Russia ministry of health approves avifavir ' '(favipiravir) for COVID-19 patients—cuts duration of illness by over 50 ' '%. ' 'https://www.trialsitenews.com/russia-ministry-of-health-approves-avifavir-favipiravir-for-covid-19-patients-cuts-duration-of-illness-by-over-50/. ' 'Accessed September 1, 2020).'}, { 'issue': '1', 'key': '10.1016/j.clinpr.2022.100145_b0135', 'doi-asserted-by': 'crossref', 'DOI': '10.1038/s41598-021-90551-6', 'article-title': 'The efficacy and safety of Favipiravir in treatment of COVID-19: a ' 'systematic review and meta-analysis of clinical trials', 'volume': '11', 'author': 'Hassanipour', 'year': '2021', 'journal-title': 'Scientific reports.'}, { 'issue': '7', 'key': '10.1016/j.clinpr.2022.100145_b0140', 'doi-asserted-by': 'crossref', 'first-page': '449', 'DOI': '10.2183/pjab.93.027', 'article-title': 'Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase', 'volume': '93', 'author': 'Furuta', 'year': '2017', 'journal-title': 'Proc. Jpn. Acad. Ser. B Phys. Biol. Sci.'}, { 'issue': '2', 'key': '10.1016/j.clinpr.2022.100145_b0145', 'doi-asserted-by': 'crossref', 'first-page': '45', 'DOI': '10.1016/S2055-6640(20)30016-9', 'article-title': 'A review of the safety of favipiravir-a potential treatment in the ' 'COVID-19 pandemic?', 'volume': '6', 'author': 'Pilkington', 'year': '2020', 'journal-title': 'J. Virus Erad.'}, { 'issue': '2', 'key': '10.1016/j.clinpr.2022.100145_b0150', 'doi-asserted-by': 'crossref', 'first-page': '242', 'DOI': '10.1002/cpt.1844', 'article-title': 'Favipiravir: Pharmacokinetics and concerns about clinical trials for ' '2019-nCoV infection', 'volume': '108', 'author': 'Du', 'year': '2020', 'journal-title': 'Clinical Pharmacology and Therapeutics'}], 'container-title': 'Clinical Infection in Practice', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://api.elsevier.com/content/article/PII:S2590170222000139?httpAccept=text/xml', 'content-type': 'text/xml', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://api.elsevier.com/content/article/PII:S2590170222000139?httpAccept=text/plain', 'content-type': 'text/plain', 'content-version': 'vor', 'intended-application': 'text-mining'}], 'deposited': { 'date-parts': [[2022, 5, 12]], 'date-time': '2022-05-12T03:11:54Z', 'timestamp': 1652325114000}, 'score': 1, 'resource': {'primary': {'URL': 'https://linkinghub.elsevier.com/retrieve/pii/S2590170222000139'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2022, 5]]}, 'references-count': 30, 'alternative-id': ['S2590170222000139'], 'URL': 'http://dx.doi.org/10.1016/j.clinpr.2022.100145', 'relation': {}, 'ISSN': ['2590-1702'], 'subject': ['General Medicine'], 'container-title-short': 'Clinical Infection in Practice', 'published': {'date-parts': [[2022, 5]]}, 'article-number': '100145'}